Core Insights - Bio-Techne Corporation reported flat net sales and organic revenue of $295.9 million for the second quarter of FY2026, with a favorable foreign currency impact of 2% and an unfavorable impact from non-recurring prior year revenue of 2% [6][8] - The company achieved a GAAP EPS of $0.24, up from $0.22 in the same quarter last year, and a 15% increase in GAAP operating income to $54.5 million [7][8] - Adjusted EPS rose to $0.46 from $0.42 year-over-year, with adjusted operating income increasing to $92.0 million, reflecting ongoing productivity and cost containment initiatives [8][9] Financial Performance - Revenue for the second quarter was $295.9 million, with reported and organic growth flat compared to the prior year [6][8] - GAAP operating margin improved to 18.4% from 16.0% in the same quarter last year, driven by profitability initiatives and the Exosome Diagnostics divestiture [7][9] - Adjusted operating margin increased to 31.1%, up 100 basis points from the prior year, indicating effective cost management [8][9] Segment Results - The Protein Sciences segment generated net sales of $215.1 million, a 2% increase from $211.6 million in the same quarter last year, although organic revenue decreased by 1% [11] - The Diagnostics and Spatial Biology segment reported net sales of $81.2 million, down 4% from $84.1 million, but organic revenue grew by 3% [12] - The operating margin for the Protein Sciences segment decreased to 39.3% from 41.2%, while the Diagnostics and Spatial Biology segment's operating margin increased to 10.4% from 3.9% [11][12] Company Overview - Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostics, generating over $1.2 billion in net sales in fiscal 2025 [13] - The company has a diverse portfolio that supports high-growth applications in science and medicine, celebrating its 50th anniversary in 2026 [4][13]